An overview of normocalcemic primary hyperparathyroidism

Purpose of reviewNormocalcemic primary hyperparathyroidism (PHPT) received special attention in the publication of the conference proceedings from the Fourth International Workshop on the Management of Asymptomatic PHPT, although much remains unknown about the disorder. Recent findingsObservational studies have found that despite maintaining normocalcemia, patients with normocalcemic PHPT have a high incidence of kidney stones and osteoporosis. Small studies focusing on the cardiovascular implications of normocalcemic PHPT have shown a possible association with hypertension and an atherogenic lipid profile, but not insulin resistance. Recent data from small cohorts show that subjects with normocalcemic PHPT respond to medical therapy and have a positive densitometric response following parathyroid surgery. SummaryThe available evidence suggests that patients with normocalcemic PHPT develop complications of PHPT, despite having normal calcium levels. Most data come from referral populations and information regarding a mild, asymptomatic form of the disease is lacking. Future research requires a standardized approach to the diagnostic criteria of normocalcemic PHPT.

[1]  A. Palermo,et al.  Effects of alendronate and vitamin D in patients with normocalcemic primary hyperparathyroidism , 2015, Osteoporosis International.

[2]  G. Cevenini,et al.  Use of cinacalcet in nephrolithiasis associated with normocalcemic or hypercalcemic primary hyperparathyroidism: results of a prospective randomized pilot study. , 2015, Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica.

[3]  Lian-tao Li,et al.  Is Normocalcemic Primary Hyperparathyroidism Harmful or Harmless? , 2015, The Journal of clinical endocrinology and metabolism.

[4]  Y. Greenman,et al.  Letter to the editor: Thiazides are not inducers of PTH secretion: a comment on normocalcemic hyperparathyroidism. , 2015, The Journal of clinical endocrinology and metabolism.

[5]  L. Rejnmark,et al.  Current issues in the presentation of asymptomatic primary hyperparathyroidism: proceedings of the Fourth International Workshop. , 2014, The Journal of clinical endocrinology and metabolism.

[6]  D. Borderie,et al.  Individual site-specific bone mineral density gain in normocalcemic primary hyperparathyroidism , 2014, Osteoporosis International.

[7]  D. Borderie,et al.  Bone mineral density evolution after successful parathyroidectomy in patients with normocalcemic primary hyperparathyroidism. , 2013, The Journal of clinical endocrinology and metabolism.

[8]  D. Bauer,et al.  Normocalcemic hyperparathyroidism and hypoparathyroidism in two community-based nonreferral populations. , 2013, Journal of Clinical Endocrinology and Metabolism.

[9]  S. Polyzos,et al.  Parathyroid hormone changes following denosumab treatment in postmenopausal osteoporosis , 2013, Clinical endocrinology.

[10]  M. Muñoz-Torres,et al.  Normocalcemic primary hyperparathyroidism: one-year follow-up in one hundred postmenopausal women , 2012, Endocrine.

[11]  F. Bandeira,et al.  Normocalcemic versus Hypercalcemic Primary Hyperparathyroidism: More Stone than Bone? , 2012, Journal of osteoporosis.

[12]  F. Keleştimur,et al.  Investigation of insulin resistance in patients with normocalcemic primary hyperparathyroidism , 2012, Endocrine.

[13]  Tracy S. Wang,et al.  Surgical Management of Normocalcemic Primary Hyperparathyroidism , 2012, World Journal of Surgery.

[14]  J. Aloia The 2011 Report on Dietary Reference Intake for Vitamin D: Where Do We Go From Here? , 2011 .

[15]  F. Bandeira,et al.  Normocalcemic primary hyperparathyroidism in clinical practice: an indolent condition or a silent threat? , 2011, Arquivos brasileiros de endocrinologia e metabologia.

[16]  N. Stern,et al.  Cardiovascular risk factors and arterial rigidity are similar in asymptomatic normocalcemic and hypercalcemic primary hyperparathyroidism. , 2010, European journal of endocrinology.

[17]  L. Mosekilde,et al.  Presentation of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. , 2009, The Journal of clinical endocrinology and metabolism.

[18]  F. Coe,et al.  New insights into the pathogenesis of idiopathic hypercalciuria. , 2008, Seminars in nephrology.

[19]  M. Rubin,et al.  Normocalcemic primary hyperparathyroidism: further characterization of a new clinical phenotype. , 2007, The Journal of clinical endocrinology and metabolism.

[20]  J. Rastad,et al.  Metabolic abnormalities in patients with normocalcemic hyperparathyroidism detected at a population-based screening. , 2006, European journal of endocrinology.

[21]  Y. Yazici,et al.  Denosumab in postmenopausal women with low bone mineral density. , 2006, The New England journal of medicine.

[22]  P. Vestergaard,et al.  Effects of long‐term treatment with loop diuretics on bone mineral density, calcitropic hormones and bone turnover , 2005, Journal of internal medicine.

[23]  Zareen Syed,et al.  Alendronate in primary hyperparathyroidism: a double-blind, randomized, placebo-controlled trial. , 2004, The Journal of clinical endocrinology and metabolism.

[24]  S. Silverberg,et al.  "Incipient" primary hyperparathyroidism: a "forme fruste" of an old disease. , 2003, The Journal of clinical endocrinology and metabolism.

[25]  P. Houillier,et al.  Normocalcemic primary hyperparathyroidism: evidence for a generalized target-tissue resistance to parathyroid hormone. , 2003, The Journal of clinical endocrinology and metabolism.

[26]  K. Kaukinen,et al.  Endocrinological disorders and celiac disease. , 2002, Endocrine reviews.

[27]  P. Vestergaard,et al.  Effects of thiazide‐ and loop‐diuretics, alone or in combination, on calcitropic hormones and biochemical bone markers: a randomized controlled study , 2001, Journal of internal medicine.

[28]  E. Siris,et al.  A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery. , 1999, The New England journal of medicine.

[29]  A. Stoll,et al.  Alterations in parathyroid dynamics in lithium-treated subjects. , 1997, The Journal of clinical endocrinology and metabolism.

[30]  E. Thurfjell,et al.  Population-based screening for primary hyperparathyroidism with serum calcium and parathyroid hormone values in menopausal women. , 1997, Surgery.

[31]  H. Genant,et al.  Alendronate treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodeling. , 1995, The American journal of medicine.

[32]  G. Kallner,et al.  Renal, thyroid and parathyroid function during lithium treatment: laboratory tests in 207 people treated for 1–30 years , 1995, Acta psychiatrica Scandinavica.

[33]  D. M. Tibbetts,et al.  STUDIES OF CALCIUM AND PHOSPHORUS METABOLISM: XVIII. On Temporary Fluctuations in the Level of Calcium and Inorganic Phosphorus in Blood Serum of Normal Individuals. , 1931, The Journal of clinical investigation.

[34]  M. Sargin,et al.  Normocalcemic hyperparathyroidism and insulin resistance. , 2015, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[35]  R. Eastell,et al.  Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Fourth International Workshop. , 2014, The Journal of clinical endocrinology and metabolism.

[36]  R. Eastell,et al.  Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the Fourth International Workshop. , 2014, The Journal of clinical endocrinology and metabolism.

[37]  S. Silverberg,et al.  Normocalcemic primary hyperparathyroidism. , 2013, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

[38]  Alison M. MacLeod KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) , 2009 .

[39]  R. Eastell,et al.  Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. , 2009, The Journal of clinical endocrinology and metabolism.

[40]  Y. Greenman,et al.  Characterization of normocalcemic primary hyperparathyroidism , 2007, Nature Clinical Practice Endocrinology &Metabolism.

[41]  J. Firpo,et al.  Evidence for secondary hyperparathyroidism in idiopathic hypercalciuria. , 1973, The Journal of clinical investigation.